China Revises Rare Disease Catalogue Procedures for First Time in Eight Years

The procedural refresh matters less for what it says than for what it enables: a revised compilation process is the mechanism through which conditions enter or leave the catalogue, and catalogue status is what typically anchors diagnosis pathways and reimbursement discussions. For rare-disease patients and the drugmakers serving them, the operative signal is timing — whether the new procedures shorten the gap between a therapy's availability and any catalogue-linked coverage. The stated goals of scientific rigor and improved coverage remain aspirational until the first catalogue cycle runs under the 2026 rules; how that cycle is sequenced is the open question.